Patent ID: 6455757
Filing Date: 2002-09-24
Classification: A01K,C12N

Abstract:
A transgenic mouse comprising, stably integrated into the genome of said mouse a first transgenic nucleotide sequence encoding bioactive transforming growth factor-&bgr;1 (TGF-&bgr;1) operably linked to a promoter and a second transgenic nucleotide sequence encoding a human amyloid precursor protein (hAPP) gene product operably linked to a promoter, wherein said first and said second transgenic nucleotide sequences are expressed;wherein, as a result of the expression of both transgenic nucleotide sequences, the transgenic mouse develops, within about three months of age, cerebrovascular amyloid deposits, and wherein, at about 12 months of age, the transgenic mouse has a significantly reduced number of neuritic amyloid plaques in the brain parenchyma, and an increase in cerebrovascular amyloid deposits, relative to a transgenic mouse that expresses a transgenic nucleotide sequence encoding a human amyloid precursor protein (hAPP) gene product and that does not express a transgenic nucleotide sequence encoding bioactive transforming growth factor-&bgr;1 (TGF-&bgr;1).